A Victory for the Propel Sinus Stent
Some of you may be aware that I am a fan of the Propel Sinus Stent inasmuch as a physician can appropriately support a particular device. I have seen success with Propel in my patients, and found a good deal of edifying data to support the manufacturer’s claims that it shortens healing times and helps to prevent complications following septoplasty and similar surgeries.
Now Propel has achieved another landmark in its march toward widespread acceptance: it will soon be fully insurance-reimbursable by one of the country’s major carriers. Here’s the release from a division of Blue Cross:
“Use of a mometasone furoate-eluting sinus implant, such as Propel, is considered medically necessary in conjunction with functional endoscopic sinus surgery (FESS) or other sinus procedure,” according to CareFirst BlueCross BlueShield. “Despite the limitations of the studies, the actions of topically applied corticosteroid drugs in conjunction with FESS are known. The Propel implant is an example of a product that releases a steroid drug safely and effectively over time. Therefore the implant is considered medically necessary when used in accordance with its approved labeling.”
The new coverage will offer assistance to a number of people enrolled in the Federal Employees Health Program, as well as millions more private citizens in the D.C. area.
It is yet another stamp of approval for a device that has helped many of my patients recover more quickly and maintain open airways following sinus surgery in Los Angeles. You can learn more about Propel, and how it’s used by many of the best sinus doctors in LA, by clicking here.